Get the Stockscreener App
60.31
3.73%
2.17
Pre-market:
64.10
3.79
+6.28%
Biomarin Pharmaceutical Inc stock is traded at $60.31, with a volume of 6.70M.
It is up +3.73% in the last 24 hours and up +4.89% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$58.14
Open:
$58.19
24h Volume:
6.70M
Relative Volume:
3.14
Market Cap:
$11.57B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
22.42
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
+3.73%
1M Performance:
+4.89%
6M Performance:
-4.07%
1Y Performance:
-28.37%
1-Day Range:
$58.00
$60.62
1-Week Range:
$56.52
$60.62
52-Week Range:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
60.31 | 11.15B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BioMarin: Q2 Earnings Snapshot - CTPost
BioMarin Pharmaceutical Inc (BMRN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results - TipRanks
BioMarin raises 2025 full-year guidance with $3.125B revenue target and advances BMN 333 - MSN
BioMarin’s Earnings Beat Forecasts And Hike Guidance For 2025 - Finimize
BioMarin (BMRN) Q2 Revenue Jumps 16% - The Motley Fool
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Earnings call transcript: Biomarin beats Q2 2025 estimates, stock rises - Investing.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars - Yahoo Finance
BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS - PR Newswire
What makes BioMarin Pharmaceutical Inc. stock price move sharplyGet real-time alerts on top-performing stocks - Jammu Links News
How does BioMarin Pharmaceutical Inc. compare to its industry peersBuild a portfolio that grows with the market - Jammu Links News
Is BioMarin Pharmaceutical Inc. a good long term investmentCapitalize on emerging industry trends - Jammu Links News
How volatile is BioMarin Pharmaceutical Inc. stock compared to the marketHigh-octane gains - Jammu Links News
What is the dividend policy of BioMarin Pharmaceutical Inc. stockSuperior trading gains - Jammu Links News
BioMarin Pharmaceuticals Appoints Ian T. Clark to Board of Directors - AInvest
When is BioMarin Pharmaceutical Inc. stock expected to show significant growthBuild capital through low-risk investments - Jammu Links News
What is BioMarin Pharmaceutical Inc. company’s growth strategySky-high profits - Jammu Links News
Is it the right time to buy BioMarin Pharmaceutical Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What are analysts’ price targets for BioMarin Pharmaceutical Inc. in the next 12 monthsSuperior investment outcomes - Jammu Links News
Published on: 2025-08-03 23:11:15 - Jammu Links News
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher in 2025Unlock powerful stock screening for profits - Jammu Links News
What are the technical indicators suggesting about BioMarin Pharmaceutical Inc.Free Bull & Bear Market Updates - Jammu Links News
How strong is BioMarin Pharmaceutical Inc. company’s balance sheetTremendous wealth creation - Jammu Links News
Is BioMarin Pharmaceutical Inc. a growth stock or a value stockMaximize returns with smart investment plans - Jammu Links News
What are BioMarin Pharmaceutical Inc. company’s key revenue driversConsistent high-yield stocks - Jammu Links News
BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect - TradingView
BioMarin Expands Board with New Director Appointment - MSN
How does BioMarin Pharmaceutical Inc. generate profit in a changing economyStock Market Entry Points To Watch Now - Jammu Links News
BioMarin Pharmaceutical appoints Ian T. Clark to board of directors - Investing.com
BioMarin Pharmaceutical Inc. Tests 50 Day MA After Sharp DeclineHigh Win Rate Trading Opportunities Detected - metal.it
BioMarin Pharmaceutical appoints Ian T. Clark to board of directors By Investing.com - Investing.com UK
BioMarin Announces Appointment of Ian T. Clark to Board of Directors - Eastern Progress
What is the risk reward ratio of investing in BioMarin Pharmaceutical Inc. stockMarket Forecast Report For Fast Growth - Jammu Links News
BioMarin Pharmaceutical Inc. Company’s Quarterly Earnings Growth: What the Numbers SayLow Risk High Return Opportunities Identified - metal.it
Trendlines Converge — Decision Point for BioMarin Pharmaceutical Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
PTC To Challenge BioMarin In PKU With Oral Sephience - insights.citeline.com
BioMarin Pharmaceutical Inc. Stock Performance After Earnings: Historical InsightsCommunity Verified Stock Suggestions Drive Volume - metal.it
BioMarin Pharmaceutical Inc. Recovery Likely Here’s What Data ShowsPattern Alert With ROI Driven Strategy Shared - metal.it
Earnings Chart Overlay Points to BioMarin Pharmaceutical Inc. UpsideWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Should I hold or sell BioMarin Pharmaceutical Inc. stock in 2025Achieve rapid wealth accumulation through smart investing - jammulinksnews.com
Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT - Insider Monkey
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):